Oruka Therapeutics
IPOA new era for chronic skin diseases
Public · Menlo Park, United States · Founded 2024 · $205.0M raised
- Headquarters
- Menlo Park, California
- Employees
- 11–50
- Founded
- 2024
- Business Model
- B2B
- Website
- orukatx.com
- Total Funding
- $205.0M
- Last Round
- $180.0M Private EquitySep 2025
- Rounds
- 2
- Type
- Public
About
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing novel monoclonal antibodies designed to set a new standard for the treatment of chronic skin diseases. The company is advancing potentially best-in-class biologics — ORKA-001 and ORKA-002 — that aim to deliver higher rates of complete disease clearance in moderate-to-severe plaque psoriasis with as few as one or two doses per year. Founded by seasoned biopharma professionals, Oruka's name reflects its mission: derived from 'or' for 'skin' and 'arukah' for 'restoration.'
Summary
Oruka Therapeutics is a Healthcare company based in Menlo Park, United States, founded in 2024. It has raised $205.0M in total across 2 rounds, most recently a $180.0M Private Equity round in Sep 2025. Investors include Viking Global, Fairmount Funds and Blackstone Multi-Asset Investing.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Apr 2026
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...